Bioethics News

Patient Deaths Unlikely to Derail Cancer Therapies

(Genetic Engineering & Biotechnology News) – The seven patient deaths disclosed recently by Juno Therapeutics and Ziopharm aren’t likely to derail cancer-fighting cell and gene therapies for years as happened with gene therapy after 18-year-old Jesse Gelsinger died in a 1999 clinical trial. But the recent deaths are sobering reminders of the risks associated with both therapies—risks that have cooled what last year had been red-hot investor enthusiasm for developers of both types of treatments.

The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.